Proactive Investors - Run By Investors For Investors
Why invest in SAR?
Sareum Holdings PLC: DEEP DIVE
OVERVIEW

Sareum Holdings primed for progress

Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
Sareum Holdings primed for progress
OVERVIEW: SAR The Big Picture
The company has two other preclinical treatments – one for autoimmune disease, the other for cancer
  • Lead drug being developed by partner Sierra Oncology

  • Data on SRA737 should be published at a leading cancer conference

  • It has two other preclinical treatments – one for autoimmune disease the other for cancer

About Sareum

Sareum Holdings PLC's (LON:SAR) most advanced programme was developed in collaboration with the Institute of Cancer Research and the CRT Pioneer Fund. It is undergoing two Phase II clinical trials conducted by licence partner Sierra Oncology. There are a further two trials planned. The drug developer has two other preclinical discoveries - focused on autoimmune disease and cancer.

SRA737

This is a checkpoint kinase 1 inhibitor, a type of drug that controls a cancer cell's response to DNA damage. Sareum’s NASDAQ-listed partner is currently refining trials of the drug following the emergence of new data. It will focus efforts on a form of ovarian cancer. This “reprioritising and enlarging” of the ongoing Phase I/II studies have meant that the publication of clinical data is now expected to take place in mid-2019. Sierra has suggested read-out will be submitted for presentation at ASCO, America’s largest cancer conference, which takes place at the end of May running into early June.

What else does Sareum have?

Earlier in the pipeline are SDC-1801, for auto-immune diseases, and SDC-1802, for cancer. Preclinical programmes have been mapped out for each discovery with the aim of getting them into the clinic in 2020. Both are members of the Janus Kinase (JAK) family and specifically are TYK2/JAK1 kinases. They work by inhibiting the activity of one or more of the Janus kinase family of enzymes.

What the broker says

Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space.”

View full SAR profile View Profile

Sareum Holdings PLC Timeline

Big Picture
February 23 2019

Related Articles

copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
Surgery
February 21 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use